Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Yu. Yu. Grabovetskay"'
Autor:
A. S. Fedorov, Yu. O. Savelyeva, Yu. Yu. Grabovetskay, L. A. Rudyuk, E. M. Kuchinskaya, M. M. Kostik
Publikováno v:
Современная ревматология, Vol 18, Iss 2, Pp 81-87 (2024)
Drug-induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia and systemic symptoms (DRESS) is a rare, potentially fatal systemic reaction characterized by multiorgan damage involving the liver, hematopoietic system and skin, and h
Externí odkaz:
https://doaj.org/article/36601aff2b684f0aac517e6a70af611c
Publikováno v:
Безопасность и риск фармакотерапии, Vol 12, Iss 3, Pp 285-298 (2024)
INTRODUCTION. Methotrexate (MTX) is the main disease-modifying antirheumatic drug (DMARD) and the gold standard for the safety and efficacy evaluation of biologicals and targeted small molecules. However, its narrow therapeutic range, interpatient va
Externí odkaz:
https://doaj.org/article/c90034379d744cd1a76784042e2f9437
Autor:
Sh. Erdes, V. I. Mazurov, I. Z. Gaydukova, O. N. Anoshenkova, I. B. Vinogradova, Yu. Yu. Grabovetskaya, S. Yu. Davidian, O. E. Epifanova, N. A. Kiryukhina, L. V. Masneva, I. V. Menshikova, O. N. Mironenko, N. E. Nikulenkova, T. V. Povarova, A. N. Polyatika, R. R. Samigullina, A. E. Sizikov, I. N. Totrov, I. F. Umnova, J. V. Usacheva, A. L. Chudinov
Publikováno v:
Научно-практическая ревматология, Vol 61, Iss 6, Pp 700-710 (2024)
Background. Netakimab has shown high efficacy in controlled clinical trials in the treatment of patients with ankylosing spondylitis (AS). This article presents results of an observational study of netakimab using in routine clinical practice.Methods
Externí odkaz:
https://doaj.org/article/7e5bc44473f34733b5ff6008d493e861
Autor:
T. V. Korotaeva, E. E. Gubar, E. Yu. Loginova, Y. L. Korsakova, E. A. Vasilenko, I.-D. Yu. Ilyevsky, L. V. Ivanova, E. Yu. Akulinushkina, P. A. Shesternya, O. V. Matveychuk, Yu. Yu. Grabovetskaya, A. A. Barakat, M. A. Korolev, E. V. Zonova, O. A. Georginova, I. V. Kolotilina, I. M. Marusenko, I. B. Vinogradova, O. B. Nesmeyanova, N. E. Grigoriadi, A. V. Petrov, D. G. Krechikova, T. V. Kropotina, S. P. Yakupova, V. I. Mazurov
Publikováno v:
Современная ревматология, Vol 17, Iss 6, Pp 22-30 (2023)
Psoriatic arthritis (PsA) is a chronic immunoinflammatory disease of the joints, spine and entheses from the group of spondyloarthritis, which is usually observed in patients with psoriasis. In recent years, the axial form of PsA (axPsA) has been act
Externí odkaz:
https://doaj.org/article/2ce507c9aff047a4aa939b461df954ab
Autor:
A. E. Karateev, E. Yu. Polishchuk, E. S. Filatova, V. N. Amirdzhanova, V. A. Nesterenko, A. S. Potapova, S. I. Glukhova, A. M. Lila, A. V. Sarapulova, A. A. Mukhin, O. S. Lyusina, L. A. Levasheva, E. V. Kryukova, D. K. Klein, N. V. Kichai, M. A. Kabalyk, N. E. Dobrokhotova, Yu. Yu. Grabovetskaya, L. A. Blagodareva, E. V. Zonova, S. M. Zwinger, P. P. Popov
Publikováno v:
Современная ревматология, Vol 16, Iss 2, Pp 34-42 (2022)
The formation of chronic musculoskeletal pain (MSP) is a multifactorial process, in its pathogenesis mechanism of central sensitization (CS) plays an important role.Objective: to evaluate the effectiveness of etoricoxib at a dose of 60 mg per day in
Externí odkaz:
https://doaj.org/article/49917ce19dd04cffa56ba55e40a8c1d2
Autor:
A. E. Karateev, Yu. V. Barysheva, Ya. V. Belokon, T. Yu. Bolshakova, Yu. Yu. Grabovetskaya, E. A. Dolzhenkova, L. N. Eliseeva, O. B. Ershova, E. V. Zonova, I. Yu. Chernova, A. O. Isakanova, M. N. Kirpikova, V. T. Komarov, E. V. Kryukova, A. I. Kulikov, D. I. Lakhin, L. A. Levasheva, L. V. Masneva, L. V. Menshikova, Yu. V. Mishina, S. V. Norina, Yu. N. Pashkovsky, A. V. Petrov, A. G. Rusanov, A. V. Sarapulova, K. A. Svodtseva, O. V. Semagina, A. N. Sudakova, S. N. Tkachenko, M. M. Toporkov, S. K. Tutelyan, G. R. Fadienko, O. S. Filonenko, O. P. Fomina, A. S. Chernov
Publikováno v:
Современная ревматология, Vol 14, Iss 4, Pp 82-90 (2020)
A combination of chondroitin and glucosamine is widely used in clinical practice as both a symptomatic and structure-modifying agent for the treatment of osteoarthritis (OA). The emergence of new drugs based on this combination substantially expands
Externí odkaz:
https://doaj.org/article/913187d83c914518970f41838708eadd
Autor:
Yu. Yu. Grabovetskaya
Publikováno v:
Современная ревматология, Vol 14, Iss 3, Pp 97-101 (2020)
Axial spondyloarthritis (axSpA) is an immune-mediated inflammatory disease that affects predominantly the sacroiliac joints and spine. The main goal of axSpA therapy is to slow down and prevent structural damages that become a main cause of disabilit
Externí odkaz:
https://doaj.org/article/9320fc9042624d389150f28fd16c5ba5